Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.
read more
Andrew M. Dahlem Ph.D. ā Chief Operating Officer at Eli Lilly and Company
Executive Bio
Dr. Andrew M. Dahlem, Ph.D has been Chief Operating Officer of Eli Lilly & Co., since 2016 and served as its Vice President of Operations for Lilly Research Laboratories since February 2007 until 2016. Dr. Dahlem has exceptional knowledge of the pharmacuetical industry A successful drug discovery and development Researcher, Dr. Dahlem has specific expertise in Drug Disposition and Toxicology. Dr. Dahlem served as Vice President of Toxicology, Drug Disposition, Pharmacokinetics and Lilly Research Labs (Europe) since January 2003 and as its Vice President of drug disposition, pharmacokinetics, discovery operations, and LRL European operations since December 2001. He joined Lilly in 1990 as a Senior Pharmacologist and served as its Head of Biochemical Toxicology since 1992 and Director of Drug Disposition and Biochemical (investigative) Toxicology since 1993. He served as Executive Director for Toxicology and Drug Disposition at Lilly since 1998 and he assumed responsibility for LRL in Europe in 1999 and for discovery operations in 2000. He serves as a Director of Indigo BioSystems, Inc. He was President of the Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists. He is a Member of the Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists and the International Society for the Study of Xenobiotics. He is a Member of the Sigma Xi Honor Society. He is a Member of the Senior Management Council. He is Adjunct Professor of Toxicology in the College of Veterinary Medicine of both Purdue University and the University of Illinois at Urbana-Champaign. Dr. Dahlem was the recipient of the Joseph O. Alberts Award for the outstanding graduate researcher in the College of Veterinary Medicine. He received his Bachelor of Science degree in Wildlife Biology from The Ohio State University in 1982 and a Doctor of Philosophy degree in Toxicology from the University of Illinois at Urbana-Champaign in 1989.
Chief Operating Officer Impact on Operations Department's Culture
Andrew M. Dahlem Ph.D. holds the highest position within the Operations department at Eli Lilly and Company ā Chief Operating Officer, and therefore has influence on the culture of the Operations department.
Are you challenged at work?
Are your company's goals clear, and are you invested in them?
Are you satisfied with your work/life balance?
Is your work environment positive or negative?
How would you rate the value & quality of meetings at your company?
Does your current company provide you meaningful opportunities for career advancement?
Executive Team Culture Ratings from Eli Lilly and Company Employees
TOP
10%
Eli Lilly and Company's Executive Team scores in the Top 10%
of similar sized companies on Comparably
of similar sized companies on Comparably
Eli Lilly and Company's Executive Team at a Glance
Based on 143 ratings, Eli Lilly and Company's employees are very satisfied with their Executive Team and give them an āAā or 76/100. On average, Men provided higher ratings for their Executive Team compared to Women. Also, the Operations department thinks more highly of the Executive Team relative to the Product department.
Eli Lilly and Company's Executive Team ranks in the Top 20% of other companies in Indianapolis, IN and Top 10% of other companies on Comparably that also have 10,000+ Employees.
×